Effective Collaboration - Team Research for Better Returns: Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Effective Collaboration - Team Research for Better Returns:

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: The Ox who wrote (3609)	8/13/2014 8:44:14 AM
From: The Ox	Read Replies (1) of 8285

RBC analyst Michael J. Yee recommended buying Intercept Pharmaceuticals (NASDAQ: ICPT) on the pullback from recent highs. Comments follow feedback from investors following Nash data. In addition, Yee raised the possibility of a takeover. "ICPT is +27% but off highs of +45% (profit taking on a stock up this much, and investors still doing work on the market opportunity, digesting the data.). We're buyers because it's significantly more de-risked and our confidence on $5B+ estimate is higher," said Yee. Yee went on to say Gilead Sciences (NASDAQ: GILD) should acquire Intercept. Other potential acquirers include Johnson & Johnson (NYSE: JNJ), Bristol-Myers Squibb (NYSE: BMY), and Merck (NYSE: MRK), "GILD should acquire ICPT or this is easy for JNJ, BMY, MRK, etc," he said. "What about all the other big indications: PSC, BAD, etc etc. Tons of other indications to go after now that a BD at pharma would love to pursue long term." RBC Capital has an Outperform rating on Intercept Pharmaceuticals with a price target of $500.00

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next